| Arthritis, Psoriatic
Orencia vs Otezla
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Orencia vs Otezla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOtezla has a higher rate of injection site reactions vs Orencia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Otezla but not Orencia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Orencia
Otezla
At A Glance
SC injection, IV infusion
Weekly (SC) or every 4 weeks (IV)
Selective T-cell costimulation modulator
Oral
Once or twice daily
PDE4 inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Acute GVH disease
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
Dosing
Rheumatoid Arthritis IV: weight-based (500-1,000 mg) infused over 30 minutes at Weeks 0, 2, and 4, then every 4 weeks; SC: 125 mg once weekly, with optional IV loading dose on Day 1.
Juvenile polyarthritis IV (>=6 yrs): 10 mg/kg (body weight <75 kg) or adult weight-based dose (>=75 kg, max 1,000 mg) at Weeks 0, 2, and 4, then every 4 weeks; SC (>=2 yrs): 50 mg (10 to <25 kg), 87.5 mg (25 to <50 kg), or 125 mg (>=50 kg) once weekly without IV loading dose.
Arthritis, Psoriatic Adult IV: weight-based (500-1,000 mg) over 30 minutes at Weeks 0, 2, and 4, then every 4 weeks; Adult SC: 125 mg once weekly without IV loading dose; Pediatric SC (>=2 yrs): 50 mg (10 to <25 kg), 87.5 mg (25 to <50 kg), or 125 mg (>=50 kg) once weekly.
Acute GVH disease IV: patients >=6 yrs: 10 mg/kg (max 1,000 mg) over 60 minutes on Day -1, then Days 5, 14, and 28 post-transplant; patients 2 to <6 yrs: 15 mg/kg on Day -1, then 12 mg/kg on Days 5, 14, and 28.
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Contraindications
—
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
Adverse Reactions
Most common (>=10%) Headache, nasopharyngitis, upper respiratory tract infection, nausea (RA); in aGVHD: anemia, hypertension, CMV reactivation/infection, pyrexia, pneumonia, epistaxis, CD4 lymphocytes decreased, hypermagnesemia, acute kidney injury.
Serious Serious infections (pneumonia, cellulitis, urinary tract infection, bronchitis, diverticulitis), malignancies (lung cancer, lymphoma), hypersensitivity reactions, acute infusion-related reactions, COPD exacerbation.
Postmarketing Vasculitis (cutaneous and leukocytoclastic), new or worsening psoriasis, non-melanoma skin cancers (basal cell and squamous cell carcinoma), angioedema, fatal anaphylaxis (IV), systemic injection reactions (SC).
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Pharmacology
Abatacept is a selective T-cell costimulation modulator that inhibits T-lymphocyte activation by binding to CD80 and CD86, thereby blocking the CD28 costimulatory interaction required for full T-cell activation; activated T lymphocytes are implicated in the pathogenesis of RA, pJIA, and PsA.
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Orencia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
UnitedHealthcare
Orencia
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Humana
Orencia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Orencia.
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OrenciaView full Orencia profile
OtezlaView full Otezla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.